Compare MIR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIR | GPCR |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | 2020 | 2023 |
| Metric | MIR | GPCR |
|---|---|---|
| Price | $14.63 | $49.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $27.25 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 4.1M | 542.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.95 | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $734.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.11 | $18.26 |
| 52 Week High | $30.28 | $94.90 |
| Indicator | MIR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 48.21 |
| Support Level | $14.11 | $43.76 |
| Resistance Level | $16.08 | $56.63 |
| Average True Range (ATR) | 0.56 | 2.47 |
| MACD | -0.01 | -0.51 |
| Stochastic Oscillator | 22.82 | 35.46 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.